Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: Effect of celecoxib and rofecoxib
Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: Effect of celecoxib and rofecoxib
No Thumbnail Available
Date
2002-06-06
Authors
Patti, Ratnakar
Gumired, Kiranmai
Reddanna, Pallu
Sutton, Leslie N.
Phillips, Peter C.
Reddy, C. Damodar
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
In this study the role of cyclooxygenase-2 (COX-2) in primitive neuroectodermal tumor (PNET) the most malignant brain tumors of childhood was investigated. COX-2 expression in human brain tumor biopsy samples (seven/seven) was about 6-8-fold higher than normal brain tissue and several PNET cell lines also express COX-2. The effect of selective COX-2 inhibitors, celecoxib and rofecoxib on the growth of two PNET cell lines (DAOY and PFSK) was determined. Celecoxib was more potent than rofecoxib in suppressing cell growth. Growth inhibition by celecoxib and rofecoxib was independent of Bcl-2 expression. Celecoxib suppressed the expression of Akt and activated the caspase-3 in DAOY and PFSK, whereas rofecoxib did not have such an effect. © 2002 Elsevier Science Ireland Ltd. All rights reserved.
Description
Keywords
Caspase-3,
Celecoxib,
Cyclooxygenases,
Primitive neuroectodermal tumors,
Rofecoxib
Citation
Cancer Letters. v.180(1)